Zejula
What Zejula is used for
Zejula is indicated: as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Zejula
- Active substance
- niraparib
- Disease area
- Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XK02
- Marketing authorisation holder
- GlaxoSmithKline Trading Services Limited
- Authorised in the EU since
- 2017
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zejula used for?
Zejula is indicated: as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
What is the active substance in Zejula?
Zejula contains niraparib.
Who makes Zejula?
The EU marketing authorisation holder is GlaxoSmithKline Trading Services Limited.
Is Zejula an orphan medicine?
Yes. Zejula is designated an orphan medicine in the EU, for a rare disease (Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU